Antisense Therapy (CML)
Targeted Antisense Oligonucleotides Degrade Leukemia Cells
Published in Gene Therapy Weekly, December 28th, 1998
CML is a pluripotent hematopoietic stem cell disease. Several research groups have studied antisense-based therapeutic approaches to this disease. However, despite progress, antisense approaches for CML remain controversial.
Avudaiappan Maran, Cornelius F. Waller, and a team of researchers from the U.S. National Institutes of Health, and the Cleveland Clinic Foundation, Ohio, examined a novel antisense oligonucleotide (ODN) approach in vitro ("2',5'-Oligoadenylate-Antisense Chimeras Cause RNase L to Selectively Degrade...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1998-12-28)
More Articles from Gene Therapy Weekly
- Hematopoietic Gene Transfer
Transduced Cord Blood Cells Maintain Reconstitutability - Cancer Gene Therapy
Elevations in Ran/TC4 Confer Costimulatory Functions to Tumor Cells - Cancer Immunotherapy
Combination Tumor Vaccine is Tumoricidal In Vivo - Cardiovascular Gene Therapy
Postischemic Contractile Dysfunction Attenuated by Gene Transfer Protocol - Gene Deliver Methods
DNA Controlled-Release Coating Facilitates Gene Transfer - Growth Factors
Promoter Region of Human Gene Is Cloned - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
